MedNexus
2022年 · 第135卷第19期
出版日期 2022-10-05电子版 ￥0.00元
MedNexus
- 全部
- Meta Analysis
- Consensus Statement
- Review Article
- Commentary
- Original Article
- Clinical Observation
- Correspondence
Meta Analysis
开放获取
流感疫苗接种与新型冠状病毒感染及其预后的关系：系统综述和荟萃分析Binshan Jiang, Qiangru Huang, Mengmeng Jia, Xinai Xue, Qing Wang, Weizhong Yang, Luzhao Feng
中华医学杂志英文版2022年 135卷 19期
DOI: 10.1097/CM9.0000000000002427
摘要
Background:
World Health Organization recommends that influenza vaccines should benefit as much of the population as possible, especially where resources are limited. Corona virus disease 2019 (COVID-19) has become one of the greatest threats to health systems worldwide. The present study aimed to extend the evidence of the association between influenza vaccination and COVID-19 to promote the former.
Methods:
In this systematic review, four electronic databases, including the Cochrane Library, PubMed, Embase, and Web of Science, were searched for related studies published up to May 2022. All odds ratios (ORs) with 95% confidence intervals (CIs) were pooled by meta-analysis.
Results:
A total of 36 studies, encompassing 55,996,841 subjects, were included in this study. The meta-analysis for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection provided an OR of 0.80 (95% CI: 0.73–0.87). The statistically significant estimates for clinical outcomes were 0.83 (95% CI: 0.72–0.96) for intensive care unit admission, 0.69 (95% CI: 0.57–0.84) for ventilator support, and 0.69 (95% CI: 0.52–0.93) for fatal infection, while no effect seen in hospitalization with an OR of 0.87 (95% CI: 0.68–1.10).
Conclusion:
Influenza vaccination helps limit SARS-CoV-2 infection and severe outcomes, but further studies are needed.
Registration:
PROSPERO, CRD42022333747.
开放获取
成人2型糖尿病患者就诊间糖化血红蛋白A1c变异性：一项系统综述和荟萃分析Furong Qu, Qingyang Shi, Yang Wang, Yanjiao Shen, Kaixin Zhou, Ewan R. Pearson, Sheyu Li
中华医学杂志英文版2022年 135卷 19期
DOI: 10.1097/CM9.0000000000002073
摘要
Background:
Current practice uses the latest measure of glycated hemoglobin (HbAlc) to facilitate clinical decision-making. Studies have demonstrated that HbAlc variability links the risk of death and complications of diabetes. However, the role of HbAlc variability is unclear in clinical practice. This systematic review summarized the evidence of visit-to-visit HbAlc variability regarding different metrics in micro- and macro-vascular complications and death in people with type 2 diabetes.
Methods:
We searched PubMed, EMBASE (via OVID), and Cochrane Central Register (CENTRAL, via OVID) for studies investigating the association between HbAlc variability and adverse outcomes in patients with type 2 diabetes and performed random-effects meta-analysis stratified by HbAlc variability metrics in terms of standard deviation (SD), coefficient of variation (CV), and HbAlc variability score (HVS).
Results:
In people with type 2 diabetes, the highest quantile of all three HbAlc variability metrics (HbAlc-standard deviation [HbAlc-SD], HbAlc-coefficient of variance [HbAlc-CV], and HVS) is associated with increased risks of all-cause mortality, cardiovascular events, progression to chronic kidney disease, amputation, and peripheral neuropathy. For example, the hazard ratio of HbAlc-SD on all-cause mortality was 1.89 with 95% confidence interval (95% CI) 1.46–2.45 (HbAlc-CV 1.47, 95% CI 1.26-1.72; HVS 1.67, 95% CI 1.34–2.09).
Conclusions:
High HbAlc variability leads to micro- and macro-vascular complications of type 2 diabetes and related death. People with type 2 diabetes and high HbAlc variability need additional attention and care for the potential adverse outcomes.
Consensus Statement
开放获取
高血压脑出血多学科管理指南Zhiyuan Yu, Chuanyuan Tao, Anqi Xiao, Cong Wu, Min Fu, Wei Dong, Ming Liu, Xuezhong Yu, Chao You
中华医学杂志英文版2022年 135卷 19期
DOI: 10.1097/CM9.0000000000001976
摘要
高血压脑出血（HICH）是指有高血压病史的患者脑实质或脑室内突然发生出血。在诊断HICH时，应排除具有潜在致病病理学（如创伤、血管结构异常、凝血或血液学疾病、全身性疾病或肿瘤）的继发性脑出血（ICH）。HICH的特点是发病率、致残率、死亡率和复发率高。2015年，中华医学会神经外科分会、中国医师协会急诊医师与卒中筛查分会、中华人民共和国国家卫生健康委员会防治专委会专家齐聚一堂，制定起草了《中国自发性脑出血管理多学科专家共识》。[
Review Article
开放获取
人羊水干细胞在创伤愈合中的应用Han Luo, Zhen Wang, Fang Qi, Dali Wang
中华医学杂志英文版2022年 135卷 19期
DOI: 10.1097/CM9.0000000000002076
摘要
Complete wound regeneration preserves skin structure and physiological functions, including sensation and perception of stimuli, whereas incomplete wound regeneration results in fibrosis and scarring. Amniotic fluid stem cells (AFSCs) would be a kind of cell population with self-renewing and non-immunogenic ability that have a considerable role in wound generation. They are easy to harvest, culture, and store; moreover, they are non-tumorigenic and not subject to ethical restrictions. They can differentiate into different kinds of cells that replenish the skin, subcutaneous tissues, and accessory organs. Additionally, AFSCs independently produce paracrine effectors and secrete them in exosomes, thereby modulating local immune cell activity. They demonstrate anti-inflammatory and immunomodulatory properties, regulate the physicochemical microenvironment of the wound, and promote full wound regeneration. Thus, AFSCs are potential resources in stem cell therapy, especially in scar-free wound healing. This review describes the biological characteristics and clinical applications of AFSCs in treating wounds and provide new ideas for the treatment of wound healing.
Commentary
开放获取
100例ABO血型不合活体肾移植的结果分析Hideki Ishida
中华医学杂志英文版2022年 135卷 19期
DOI: 10.1097/CM9.0000000000002332
摘要
到1980年底，由于用于移植的尸体器官供应非常有限，日本团体已经开始了ABO不相容肾移植项目。从那时起，他们结合血浆置换和脾切除术成功地完成了跨越血型屏障的移植。在日本，随着2000年他克莫司（FK）/霉酚酸酯（MMF）联合用药和2005年利妥昔单抗的开发，ABO血型不合移植的策略发生了变化。[
Original Article
开放获取
100例ABO血型不合活体肾移植的结果Saifu Yin, Qiling Tan, Youmin Yang, Fan Zhang, Turun Song, Yu Fan, Zhongli Huang, Tao Lin, Xianding Wang
中华医学杂志英文版2022年 135卷 19期
DOI: 10.1097/CM9.0000000000002138
摘要
Background:
Although ABO-incompatible (ABOi) kidney transplantation (KT) has been performed successfully, a standard preconditioning regimen has not been established. Based on the initial antidonor ABO antibody titers, an individualized preconditioning regimen is developed, and this study explored the efficacy and safety of the regimen.
Methods:
From September 1, 2014, to September 1, 2020, we performed 1668 consecutive living-donor KTs, including 100 ABOi and 1568 ABO-compatible (ABOc) KTs. ABOi KT recipients (KTRs) with a lower antibody titer (≤1:8) were administered oral immunosuppressive drugs (OIs) before KT, while patients with a medium titer (1:16) received OIs plus antibody-removal therapy (plasma exchange/double-filtration plasmapheresis), patients with a higher titer (≥1:32) were in addition received rituximab (Rit). Competing risk analyses were conducted to estimate the cumulative incidence of infection, acute rejection (AR), graft loss, and patient death.
Results:
After propensity score analyses, 100 ABOi KTRs and 200 matched ABOc KTRs were selected. There were no significant differences in graft and patient survival between the ABOi and ABOc groups (P = 0.787, P= 0.386, respectively). After using the individualized preconditioning regimen, ABOi KTRs showed a similar cumulative incidence of AR (10.0% vs. 10.5%, P= 0.346). Among the ABOi KTRs, the Rit-free group had a similar cumulative incidence of AR (P = 0.714) compared to that of the Rittreated group. Multivariate competing risk analyses revealed that a Rit-free regimen reduced the risk of infection (HR: 0.31; 95% CI: 0.12–0.78, P = 0.013). Notably, antibody titer rebound was more common in ABOi KTRs receiving a Rit-free preconditioning regimen (P = 0.013) than those receiving Rit. ABOi KTRs with antibody titer rebound had a 2.72-fold risk of AR (HR: 2.72, 95% CI: 1.01–7.31, P = 0.048). ABOi KTRs had similar serum creatinine and estimated glomerular filtration rate compared to those of ABOc KTRs after the first year.
Conclusions:
An individualized preconditioning regimen can achieve comparable graft and patient survival rates in ABOi KT with ABOc KT. Rit-free preconditioning effectively prevented AR without increasing the risk of infectious events in those with lower initial titers; however, antibody titer rebound should be monitored.
开放获取
中国早期人表皮生长因子受体2阳性乳腺癌的新辅助治疗：一项多中心真实世界研究（CSBrS-015）Yuanjia Cheng, Hongyu Xiang, Ling Xin, Xuening Duan, Yinhua Liu, Chinese Society of Breast Surgery (CSBrS), Chinese Society of Surgery of Chinese Medical Association
中华医学杂志英文版2022年 135卷 19期
DOI: 10.1097/CM9.0000000000002197
摘要
Background:
Pertuzumab has been approved for application in China by the National Medical Products Administration, and both national and international guidelines make recommendations for the use of neoadjuvant treatment with trastuzumab or trastuzumab + pertuzumab plus chemotherapy regimens for patients with indications. The goal of this study was to investigate the short-term clinical efficacy of the neoadjuvant therapies trastuzumab and trastuzumab+pertuzumab for patients with early human epidermal growth factor receptor 2 (HER2)-positive breast cancer in China.
Methods:
A real-world study was conducted using the clinicopathological data of patients with early HER2-positive breast cancer who were admitted to the member hospitals of the Chinese Society of Breast Surgery, Chinese Surgical Society of Chinese Medical Association between March 2019 and December 2020. This study analyzed the efficacy and tolerance of trastuzumab+chemotherapy and trastuzumab+pertuzumab+chemotherapy in patients with early HER2-positive breast cancer. The Response Evaluation Criteria in Solid Tumors 1.1 was adopted to evaluate clinical efficacy. The pathological efficacy was evaluated using the MillerPayne grade. The Common Terminology Criteria for Adverse Events (version 5.0) was adopted to evaluate adverse events (AEs). The propensity scores were subjected to propensity score matching using the R language (1:1 matching with a maximum allowable difference of 0.05 between the two groups). Efficacy was compared using the chi-square test, and correlation analysis was performed using linear regression.
Results:
A total of 1032 patients with early HER2-positive breast cancer met the enrollment criteria and were included in this study. Among these patients, 472 received neoadjuvant trastuzumab+chemotherapy (the trastuzumab group), and 560 received neoadjuvant trastuzumab+pertuzumab+chemotherapy (the trastuzumab+pertuzumab group). The overall pathologic complete response (pCR) rate was 47.2% (487/1032), while the pCR rates of the trastuzumab and trastuzumab+pertuzumab groups were 34.5% (163/472) and 57.9% (324/560), respectively, and the difference was significant (P < 0.001). The incidence of grade 4 AEs was 24/321 (7.5%) in the trastuzumab+pertuzumab group, and there were no cases in which the left ventricular ejection fraction decreased by more than 10%.
Conclusions:
Patients in the trastuzumab+pertuzumab group had a higher pCR rate than those in the trastuzumab group, and the toxic side effects were tolerable.
开放获取
肝硬化患者内镜逆行胰胆管造影相关危险因素分析：一项多中心、回顾性、临床研究Jielin Li, Jiexuan Hu, Peng Li, Yongdong Wu, Yongjun Wang, Ming Ji, Haiyang Hua, Wenbin Ran, Yanglin Pan, Shutian Zhang
中华医学杂志英文版2022年 135卷 19期
DOI: 10.1097/CM9.0000000000002248
摘要
Background:
Endoscopic retrograde cholangiopancreatography (ERCP) is the endoscopic modality of choice for the treatment of biliary and pancreatic diseases. However, patients with cirrhosis, particularly those with decompensated cirrhosis, are believed to be at increased risk for complications associated with ERCP. There is a paucity of literature describing the outcomes of ERCP for patients with cirrhosis. This study aimed to investigate the outcomes of ERCP for cirrhosis patients, especially adverse events, and evaluated its safety and efficacy.
Methods:
We performed a multicenter, retrospective study of all patients at Beijing Friendship Hospital affiliated to Capital Medical University, Xijing Hospital affiliated to Air Force Military Medical University, Beijing Youan Hospital affiliated to Capital Medical University, and the Fifth Medical Center of the People’s Liberation Army General Hospital from June 2003 to August 2019. The adverse events of inpatient ERCP for patients with (n = 182) and without liver cirrhosis (controls; n = 385) were compared.
Results:
A total of 567 patients underwent ERCP between January 2003 and December 2019 were enrolled in this study. Compared to patients without cirrhosis, patients with cirrhosis were at higher risk for postoperative complications (odds ratio [OR], 4.172; 95% confidence interval [CI], 1.232–7.031; P < 0.001) such as postoperative pancreatitis (OR, 2.026; 95% CI, 1.002–4.378; P= 0.001) and cholangitis (OR, 3.903; 95% CI, 1.001–10.038; P= 0.036). The main indications for ERCP for patients with cirrhosis in this study included choledocholithiasis (101 cases; 55.5%), benign bile duct strictures (46 cases; 25.3%), and malignant bile duct strictures (28 cases; 15.4%). Among them, 23 patients (12.6%) underwent balloon dilation and 79 patients (43.4%) underwent sphincterotomy. Of the patients with cirrhosis, delayed bleeding occurred in ten patients (5.5%), postoperative pancreatitis occurred in 80 patients (44.0%), and postoperative cholangitis occurred in 25 patients (13.7%). An additional multivariate analysis showed that the total bilirubin (TBIL) level (OR, 4.58; 95% CI, 2.37–6.70) and Child-Pugh score of C (OR, 3.11; 95% CI, 1.04–5.37) were risk factors for postoperative complications in patients with cirrhosis.
Conclusions:
Compared with the general population of patients undergoing ERCP, patients with cirrhosis were more prone to postoperative pancreatitis and cholangitis. TBIL levels and Child-Pugh scores were risk factors for postoperative complications in patients with cirrhosis.
开放获取
胰腺导管上皮细胞来源的外泌体miR-485-3p通过靶向PAK1抑制胰腺癌转移Mingzhe Li, Jiaxin Zhou, Zhengkui Zhang, Jisong Li, Feng Wang, Ling Ma, Xiaodong Tian, Zebin Mao, Yinmo Yang
中华医学杂志英文版2022年 135卷 19期
DOI: 10.1097/CM9.0000000000002154
摘要
Background:
Cell competition is an important feature in pancreatic cancer (PC) progression, but the underlying mechanism remains elusive. This study aims to explore the role of exosomes derived from normal pancreatic ductal epithelial cells involved in PC progression.
Methods:
PC cells and pancreatic stellate cells (PSCs) were treated with exosomes isolated from pancreatic ductal epithelial cells. Cell proliferation was assessed by CCK8 assays. Cell migration and invasion were assessed by Transwell assays. PC and matched adjacent non-tumor tissue specimens were obtained from 46 patients pathologically diagnosed with PC at Peking University First Hospital from 2013 to 2017. Tissue miR-485-3p and p21-activated kinase-1 (PAK1) expression was examined by real-time polymerase chain reaction (RT-PCR), and the relationship of the two was analyzed using Pearman’s product-moment correlation. The clinical significance of miR-485-3p was analyzed using the Chi-square test, Wilcoxon rank-sum test, and Fisher exact probability, respectively. The binding of miR-485-3p to PAK1 5＇-untranslated region (5＇-UTR) was examined by luciferase assay. PC cells were xenografted into nude mice as a PC metastasis model.
Results:
Exosomes from pancreatic ductal epithelial cells suppressed PC cell migration and invasion as well as the secretion and migration of PSCs. MiR-485-3p was enriched in the exosomes of pancreatic ductal epithelial cells but deficient in those of PC cells and PSCs, in accordance with the lower level in PSCs and PC cells than that in pancreatic ductal cells. And the mature miR-485-3p could be delivered into these cells by the exosomes secreted by normal pancreatic duct cells, to inhibit PC cell migration and invasion. Clinical data analysis showed that miR-485-3p was significantly decreased in PC tissues (P < 0.05) and was negatively associated with lymphovascular invasion (P = 0.044). As a direct target of miR-485-3p, PAK1 was found to exert an inhibitory effect on PC cells, and there was a significantly negative correlation between the expression levels of miR-485-3p and PAK1 (r = -0.6525, P < 0.0001) in PC tissues. Moreover, miR-485-3p could suppress PC metastasis in vivo by targeting p21-activated kinase-1.
Conclusions:
Exosomal miR-485-3p delivered by normal pancreatic ductal epithelial cells into PC cells inhibits PC metastasis by directly targeting PAK1. The restoration of miR-485-3p by exosomes or some other vehicle might be a novel approach for PC treatment.
开放获取
晚期肝细胞癌化疗新策略的多中心回顾性研究Juxian Sun, Chang Liu, Jie Shi, Nanya Wang, Dafeng Jiang, Feifei Mao, Jingwen Gu, Liping Zhou, Li Shen, Wan Yee Lau 等
中华医学杂志英文版2022年 135卷 19期
DOI: 10.1097/CM9.0000000000001952
摘要
Background:
Chemotherapy is a common treatment for advanced hepatocellular carcinoma, but the effect is not satisfactory. The study aimed to retrospectively evaluate the effects of adding all-trans-retinoic acid (ATRA) to infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) for advanced hepatocellular carcinoma (HCC).
Methods:
We extracted the data of patients with advanced HCC who underwent systemic chemotherapy using FOLFOX4 or ATRA plus FOLFOX4 at the Eastern Hepatobiliary Surgery Hospital, First Hospital of Jilin University, and Zhejiang Sian International Hospital and retrospectively compared for overall survival. The Cox proportional hazards model was used to calculate the hazard ratios for overall survival and disease progression after controlling for age, sex, and disease stage.
Results:
From July 2013 to July 2018, 111 patients with HCC were included in this study. The median survival duration was 14.8 months in the ATRA plus FOLFOX4 group and 8.2 months in the FOLFOX4 only group (P < 0.001). The ATRA plus FOLFOX4 group had a significantly longer median time to progression compared with the FOLFOX4 group (3.6 months vs. 1.8 months, P < 0.001). Hazard ratios for overall survival and disease progression were 0.465 (95% confidence interval: 0.298–0.726; P = 0.001) and 0.474 (0.314–0.717; P < 0.001) after adjusting for potential confounders, respectively.
Conclusion:
ATRA plus FOLFOX4 significantly improves the overall survival and time to disease progression in patients with advanced HCC.
开放获取
免疫性血小板减少症患者艾曲泊帕与重组人血小板生成素转换的观察性研究Xuan Cai, Haixia Fu, Xiangyu Zhao, Jin Lu, Qian Jiang, Yingjun Chang, Xiaojun Huang, Xiaohui Zhang
中华医学杂志英文版2022年 135卷 19期
DOI: 10.1097/CM9.0000000000002346
摘要
Background:
Recombinant human thrombopoietin (rh-TPO) and eltrombopag are two distinct TPO receptor agonists (TPO-RAs) with different mechanisms. During the pandemic, when immunosuppressive medications are controversial, switching to another TPO-RA may be worth exploring in patients who do not benefit from their first TPO-RA. We investigated the outcomes of switching from rh-TPO to eltrombopag or vice versa in immune thrombocytopenia (ITP) patients.
Methods:
This prospective, open-label, observational investigation included 96 adult ITP patients who needed to switch between rh-TPO and eltrombopag between January 2020 and January 2021 at Peking University People’s Hospital in China. The study evaluated response rates and platelet counts at different time points after the switch, bleeding events, time to response, duration of response, and adverse events.
Results:
At 6 weeks after switching, response was observed in 21/49 patients (43%) who switched for inefficacy and 34/47 patients (72%) who switched for non-efficacy-related issues. In the inefficacy group, 9/27 patients (33%) responded to eltrombopag, and 12/22 patients (55%) responded to rh-TPO. In the non-efficacy-related group, 21/26 (81%) and 13/21 (62%) patients in the eltrombopag and rh-TPO groups maintained their response rates at 6 weeks after switching, respectively. Response at 6 months was achieved in 24/49 patients (49%) switching for inefficacy and 37/47 patients (79%) switching for non-efficacy issues. In the inefficacy group, 13/27 patients (48%) responded to eltrombopag, and 11/22 patients (50%) responded to rh-TPO. In the non-efficacy-related group, 22/26 patients (85%) and 15/21 patients (71%) in the eltrombopag and rh-TPO groups maintained their response rates at 6 months after switching, respectively. Both eltrombopag and rh-TPO were well tolerated.
Conclusions:
Our study confirmed the safety and effectiveness of switching between rh-TPO and eltrombopag for ITP patients who had no response to or experienced adverse events with their first TPO-RA. When the switch was motivated by other reasons, including patient preference and platelet count fluctuations, the probability of response was high.
Registration:
ClinicalTrials.gov, NCT04214951.
Clinical Observation
开放获取
血清HBV RNA作为丙氨酸氨基转移酶正常的慢性HBeAg阳性HBV感染者病毒学应答的预测因子Jiandan Qian, Chi Zhang, Huaie Liu, Guiqiang Wang, Hong Zhao
中华医学杂志英文版2022年 135卷 19期
DOI: 10.1097/CM9.0000000000002122
摘要
根据现行指南，HBV DNA阳性但丙氨酸氨基转移酶（ALT）水平正常的慢性乙型肝炎病毒（HBV）感染患者目前不需要抗病毒治疗。[
Correspondence
开放获取
氨甲环酸对房颤全关节置换术患者血管闭塞事件及围手术期复苏的影响Shangkun Tang, Zongke Zhou, Jing Yang, Pengde Kang, Bin Shen, Fuxing Pei, Xiaojun Shi
中华医学杂志英文版2022年 135卷 19期
DOI: 10.1097/CM9.0000000000002114
摘要
致编辑：氨甲环酸（TXA）最近在骨科手术中变得流行，因为它在减少失血、输血率和死亡率方面的功效而不增加深静脉血栓形成的风险。[
开放获取
益生菌混合物VSL#3通过调节炎症和Wnt/β-catenin途径预防小鼠和细胞中溃疡性结肠炎相关的致癌作用Wenbin Li, Yanan Wang, Chunsaier Wang, Hongying Wang, Yiming Ma, Hong Yang, Xinhua Zhao, Xiaomin Hu, John Y. Kao, Jiaming Qian 等
中华医学杂志英文版2022年 135卷 19期
DOI: 10.1097/CM9.0000000000002035
摘要
致编辑：预防溃疡性结肠炎（UC）相关的致癌作用越来越受到关注。肠道微生物群在维持肠道屏障和免疫功能方面发挥着重要作用。2015年5月从Sigma-Tau pharmaceuticals(De Simone制剂)购买的益生菌混合物VSL#3是以下的混合物：干酪乳杆菌、植物乳杆菌、嗜酸乳杆菌、德氏乳杆菌亚种。保加利亚菌、长双歧杆菌、短双歧杆菌、婴儿双歧杆菌和唾液链球菌并含有45亿个活细菌菌落。[
开放获取
N6-甲基腺苷（m6A）相关基因对胃癌预后的预测价值及其与肿瘤微环境的相关性Tengfei Yin, Lang Zhao, Shukun Yao
中华医学杂志英文版2022年 135卷 19期
DOI: 10.1097/CM9.0000000000002137
摘要
致编辑：胃癌（GC）对全球人类健康构成巨大威胁。N6-甲基腺苷（m6A）RNA甲基化是最丰富的转录后RNA修饰，在RNA剪接、输出、加工、翻译和衰变中起着至关重要的作用。[
开放获取
强制空气加温与无空气加温对择期手术患者围手术期低温的比较Bin Ji, Mengxue He, Hang Chen, Yu Chen, Siyuan Wang, Lyucheng Yang, Weihong Xu, Nanping Shen
中华医学杂志英文版2022年 135卷 19期
DOI: 10.1097/CM9.0000000000002145
摘要
致编辑：体温过低被描述为患者的核心温度降低到等于或<36°，这是择期手术患者中常见且严重的并发症。[
开放获取
基于深度学习的冠状动脉CT血管造影后处理和诊断报告系统性能评价：临床对比研究Nan Luo, Yi He, Jitao Fan, Ning Guo, Guang Yang, Yuanyuan Kong, Jianyong Wei, Tao Bi, Jie Zhou, Jiaxin Cao 等
中华医学杂志英文版2022年 135卷 19期
DOI: 10.1097/CM9.0000000000001913
摘要
致编辑：冠状动脉计算机断层扫描血管造影（CCTA）已越来越广泛地用于诊断冠状动脉疾病。[
开放获取
隧道式套囊导管尖端位于下腔静脉的血液透析患者的导管失败和死亡率Lu Cheng, Qian Ren, Gang Yu, Shenju Gou, Tianlei Cui, Ping Fu
中华医学杂志英文版2022年 135卷 19期
DOI: 10.1097/CM9.0000000000002132
摘要
致编辑：永久性血管通路是血液透析依赖患者的维持生命的措施。通常，隧道套囊导管（TCC）被认为是动静脉瘘（AVF）或动静脉移植物（AVG）的桥接通路，指南不鼓励TCC作为永久性血管通路的首选，因为并发症风险较高，预期使用寿命较短。[
开放获取
女性乳腺癌幸存者中肝脂肪变性和代谢相关脂肪性肝病的患病率Shen Tian, Hao Li, Renhua Li, Liang Ran, Shu Li, Juan Wu, Zhou Xu, Xinyu Liang, Yuling Chen, Jun Xiao 等
中华医学杂志英文版2022年 135卷 19期
DOI: 10.1097/CM9.0000000000002121
摘要
致编辑：非酒精性脂肪性肝病（NAFLD）在亚洲流行，据报道在中国的患病率为24%至36%。[
开放获取
小说BRF1两名中年小脑面牙综合征同胞的突变Xin Zhao, Yan Lan, Jinfeng Miao, Guo Li, Wenzhe Sun, Xiuli Qiu, Suiqiang Zhu, Zhou Zhu
中华医学杂志英文版2022年 135卷 19期
DOI: 10.1097/CM9.0000000000001901
摘要
致编辑：小脑-面-牙综合征（CFDS）是一种罕见的常染色体隐性（AR）神经发育疾病，以小脑发育不全和智力残疾、面部畸形、身材矮小、小头畸形和牙齿异常为特征。[
开放获取
应用RNA测序技术探讨推拿对坐骨神经损伤大鼠腓肠肌的修复机制Taotao Lyu, Zhifeng Liu, Tianyuan Yu, Mengqian Lu, Yingqi Zhang, Yi Jiao, Hourong Wang, Yajing Xu, Qian Guan
中华医学杂志英文版2022年 135卷 19期
DOI: 10.1097/CM9.0000000000001960
摘要
致编辑：周围神经损伤（PNI）是指周围神经丛、神经干或其分支在外力作用下的损伤。骨骼肌来源的细胞具有很强的分泌功能，同时可以分化为雪旺细胞样细胞或其他细胞类型，因此可以有效地促进周围神经的再生。[
开放获取
整合网络药理学和蛋白质组学揭示五藏温阳化瘀汤对血管性痴呆的认知改善作用Yuhao Sun, Xiaoyu Wen, Zhuoxian Li, Lijing Xu, Meng Xia
中华医学杂志英文版2022年 135卷 19期
DOI: 10.1097/CM9.0000000000001958
摘要
致编辑：血管性痴呆（Vascular dementia，VD）是一种由多种脑血管因素引起的以认知功能障碍和智力下降为特征的临床疾病。中老年人VD的高发已成为世界性的重大医学和社会问题。[
本期目次
下载本期封面 下载本期目录
